Descripción del proyecto
Garantías para la capacidad europea de producir radioisótopos médicos
La Unión Europea es el principal operador mundial de reactores de investigación y proveedor de radioisótopos médicos. El uranio poco enriquecido (UPE) resulta fundamental para garantizar el suministro de los combustibles y los objetivos de los reactores de investigación. El éxito depende de las soluciones tecnológicas para convertir el uranio muy enriquecido en UPE en reactores de investigación. El proyecto EU-QUALIFY, financiado con fondos europeos, reunirá a un equipo multidisciplinario de expertos, que incluirá a diseñadores y fabricantes de combustibles, operadores de reactores e investigadores, para que estos combustibles y la capacidad de fabricarlos cumplan los requisitos. Los hallazgos de este proyecto garantizarán la disponibilidad de reactores de investigación de alto rendimiento en Europa, que producen la mayoría de los isótopos médicos.
Objetivo
One of the biggest challenges for European research reactors is securing their nuclear fuel supply to ensure a sustainment of medical isotopes for Europe and the world. This is particularly true for the few operating High Performance Research Reactors (HPRRs) in Europe, which produce the vast majority of medical isotopes. The obligation to convert them from high to low enriched uranium (LEU) nuclear fuels while keeping similar radioisotopes production ratios makes it necessary to develop higher uranium density fuels. The R&D related to that topic was started in previous EURATOM projects (HERACLES-CP and LEU-FOREvER). The main goal of the EU-QUALIFY project is to qualify such fuels and qualify the capability to fabricate such fuels. This will be done by a multi-disciplinary consortium composed of fuel designers/manufactures, reactor operators, research organizations and a university, namely: SCK CEN, CEA, CERCA, ILL, TUM, and G-INP.
The EU-QUALIFY project will build on previous LEU fuel development work with specific focus on the qualification of three particular types of fuels: the dispersed U-Mo, the monolithic U-Mo and the high-loaded dispersed U3Si2 fuels. This qualification will be accomplished through fabrication and concurrent qualification of pilot manufacturing equipment and processes, irradiation under representative irradiation conditions, post-irradiation examinations, as well as modelling of the in-pile behavior to support LEU conversion safety analyses.
This project will contribute to ensuring the availability of HPPR’s, and thus enhance the security of the EU’s capacity in the production of medical radioisotopes. It will thus contribute to health care through provision of innovative medical radioisotopes necessary for diagnostic and therapy and will support European industry by maintaining access to research reactor irradiation capabilities.
Ámbito científico
Programa(s)
- H2020-Euratom - Euratom Main Programme
- H2020-Euratom-1. - Indirect actions
Régimen de financiación
RIA - Research and Innovation actionCoordinador
1160 Bruxelles / Brussel
Bélgica